Literature DB >> 8408180

Protein kinase C and adenylate cyclase as targets for growth inhibition of human gastric cancer cells.

M Piontek1, K J Hengels, R Porschen, G Strohmeyer.   

Abstract

In the human gastric adenocarcinoma cell line AGS the effects of the protein-kinase-C-activating phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA), the protein kinase C inhibitor staurosporine, the adenylate-cyclase activating agent forskolin, and the permeable dibutyryl-adenosine 3',5'-monophosphate (Bt2cAMP) on the proliferation were assessed. Cell counting followed 5 days of incubation. Prolonged activation of protein kinase C by TPA, inhibition of protein kinase C by staurosporine, activation of adenylate cyclase by forskolin or a direct increase of the intracellular cAMP level all result in a dose-dependent growth inhibition of AGS gastric tumour cells. Half-maximal inhibition was achieved at 100 pM for TPA, 1 nM for staurosporine, 20 microM for forskolin, and 600 microM for Bt2cAMP. It is concluded that protein kinase C and adenylate cyclase play a fundamental role in the growth of AGS gastric cancer cells. Interference with these enzymes involved in the signal transduction of growth regulation in tumour cells may represent a target in the development of new antiproliferative principles.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8408180     DOI: 10.1007/bf01195338

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  18 in total

1.  Staurosporine, a protein kinase C inhibitor interferes with proliferation of arterial smooth muscle cells.

Authors:  H Matsumoto; Y Sasaki
Journal:  Biochem Biophys Res Commun       Date:  1989-01-16       Impact factor: 3.575

2.  Immunocytochemical evidence for phorbol ester-induced protein kinase C translocation in HL60 cells.

Authors:  M Shoji; P R Girard; G J Mazzei; W R Vogler; J F Kuo
Journal:  Biochem Biophys Res Commun       Date:  1986-03-28       Impact factor: 3.575

3.  The heterogeneity of protein kinase C in various rat tissues.

Authors:  Y Kosaka; K Ogita; K Ase; H Nomura; U Kikkawa; Y Nishizuka
Journal:  Biochem Biophys Res Commun       Date:  1988-03-30       Impact factor: 3.575

Review 4.  Studies and perspectives of protein kinase C.

Authors:  Y Nishizuka
Journal:  Science       Date:  1986-07-18       Impact factor: 47.728

5.  Altered function of protein kinase C and cyclic adenosine monophosphate-dependent protein kinase in a cell line derived from a mouse lung papillary tumor.

Authors:  K M Nicks; K A Droms; T Fossli; G J Smith; A M Malkinson
Journal:  Cancer Res       Date:  1989-09-15       Impact factor: 12.701

6.  Mechanism of inhibitory action of prostaglandins on the growth of human gastric carcinoma cell line KATO III.

Authors:  A Nakamura; T Yamatani; T Fujita; T Chiba
Journal:  Gastroenterology       Date:  1991-10       Impact factor: 22.682

7.  Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251.

Authors:  E Andrejauskas-Buchdunger; U Regenass
Journal:  Cancer Res       Date:  1992-10-01       Impact factor: 12.701

8.  Differentiation of Dunn osteosarcoma cells in response to dibutyryl cyclic 3',5'-adenosine monophosphate.

Authors:  M Kanamori; H Matsui; K Yudoh; A Maeda; K M Kadowaki; H Tsuji; H Ochiai; S Tatezaki
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

9.  Characterization of phorbol ester receptors and their down-modulation in GH4C1 rat pituitary cells.

Authors:  S Jaken; A H Tashjian; P M Blumberg
Journal:  Cancer Res       Date:  1981-06       Impact factor: 12.701

10.  12-O-tetradecanoylphorbol 13-acetate induced differentiation in human lung squamous carcinoma cells.

Authors:  G J Rabiasz; S P Langdon; L Anderson; A A Ritchie; W R Miller; J F Smyth
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

View more
  1 in total

1.  Forskolin exerts anticancer roles in non-Hodgkin's lymphomas via regulating Axin/β-catenin signaling pathway.

Authors:  Hailei Wang; Chunyan Lou; Na Ma
Journal:  Cancer Manag Res       Date:  2019-02-19       Impact factor: 3.989

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.